IL88502A - Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor - Google Patents

Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor

Info

Publication number
IL88502A
IL88502A IL88502A IL8850288A IL88502A IL 88502 A IL88502 A IL 88502A IL 88502 A IL88502 A IL 88502A IL 8850288 A IL8850288 A IL 8850288A IL 88502 A IL88502 A IL 88502A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
converting enzyme
enzyme inhibitor
angiotensin converting
Prior art date
Application number
IL88502A
Other languages
English (en)
Other versions
IL88502A0 (en
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of IL88502A0 publication Critical patent/IL88502A0/xx
Publication of IL88502A publication Critical patent/IL88502A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL88502A 1987-12-14 1988-11-25 Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor IL88502A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13245787A 1987-12-14 1987-12-14
US18882788A 1988-05-02 1988-05-02

Publications (2)

Publication Number Publication Date
IL88502A0 IL88502A0 (en) 1989-06-30
IL88502A true IL88502A (en) 1993-04-04

Family

ID=26830371

Family Applications (1)

Application Number Title Priority Date Filing Date
IL88502A IL88502A (en) 1987-12-14 1988-11-25 Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor

Country Status (9)

Country Link
EP (1) EP0321221A3 (fr)
JP (1) JPH0222235A (fr)
KR (1) KR890009413A (fr)
CN (1) CN1034312A (fr)
AU (1) AU623615B2 (fr)
DK (1) DK694188A (fr)
HU (1) HU206614B (fr)
IL (1) IL88502A (fr)
PT (1) PT89208A (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU199681B (en) * 1986-11-03 1990-03-28 Sandoz Ag Process for producing new pharmaceutical composition against hypertension and atonic cardiac decomposition
EP0331609A3 (fr) * 1988-01-27 1992-07-01 Hoechst Aktiengesellschaft Inhibiteurs de l'enzyme de conversion à activité psychotrope
US5093129A (en) * 1989-01-30 1992-03-03 E. R. Squibb & Sons, Inc. Method for treating addiction to a drug of abuse employing an ace inhibitor
CA2007525A1 (fr) * 1989-01-30 1990-07-30 Zola P. Horovitz Methode pour faciliter l'obeissance a un regime alimentaire par l'emploi d'un inhibiteur de l'enzyme de conversion de l'angiotensine
US5089502A (en) * 1989-06-02 1992-02-18 E. R. Squibb & Sons, Inc. Method for preventing or treating anxiety employing a calcium channel blocker
EP0491878B1 (fr) * 1989-08-16 1997-02-19 Chiron Corporation Compositions pour l'inhibition de la formation d'hormones proteiques et emplois de celles-ci
CA2021408A1 (fr) * 1989-08-31 1991-03-01 Luana R. C. Moore Methode de traitement de l'hypermotilite de l'intestin par l'emploi d'un inhibiteur
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
TW201039839A (en) * 2009-03-27 2010-11-16 Calpis Co Ltd Composition for regulating antonomic nervous activity and method for regulating autonomic nervous

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
CA1323833C (fr) * 1987-04-28 1993-11-02 Yatindra M. Joshi Compositions pharmaceutiques sous forme de granules et methode de fabrication

Also Published As

Publication number Publication date
CN1034312A (zh) 1989-08-02
IL88502A0 (en) 1989-06-30
DK694188A (da) 1989-06-15
EP0321221A2 (fr) 1989-06-21
JPH0222235A (ja) 1990-01-25
AU623615B2 (en) 1992-05-21
HUT48817A (en) 1989-07-28
PT89208A (pt) 1989-12-29
HU206614B (en) 1992-12-28
DK694188D0 (da) 1988-12-13
EP0321221A3 (fr) 1991-04-03
AU2640488A (en) 1989-06-15
KR890009413A (ko) 1989-08-01

Similar Documents

Publication Publication Date Title
AU2092988A (en) Dental calculus inhibiting compositions
AU1025588A (en) Novel peptidase inhibitors
GB8710965D0 (en) Pharmaceutical compositions
AU1880588A (en) Corrosion inhibiting compositions
GB8818447D0 (en) Tripeptides & pharmaceutical compositions containing them
ZA884838B (en) Dopamine-beta-hydroxylase inhibitors
EG18652A (en) Pharmaceutical compositions
IL88502A (en) Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
ZA883851B (en) Dopamine-beta-hydroxylase inhibitors
ZA889709B (en) Dopamine-beta-hydroxylase inhibitors
ZA889667B (en) Dopamine-beta-hydroxylase inhibitors
ZA882100B (en) Dopamine-beta-hydroxylase inhibitors
ZA8892B (en) Dopamine-beta-hydroxylase inhibitors
AU7409487A (en) Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors
GB8713091D0 (en) Pharmaceutical compositions
GB2224206B (en) Unit dosage formulation of an angiotensin converting enzyme inhibitor
PH24458A (en) Novel angiotensin converting enzyme inhibitors
ZA836068B (en) Angiotensin-converting enzyme inhibitors
AU3334184A (en) Compounds being angiotensin converting enzyme inhibitors
GB2179655B (en) Angiotensin converting enzyme inhibiting compounds
IE872190L (en) Pharmaceutical compositions comprising¹dopamine-beta-hydroxylase inhibitors
ZA882275B (en) Dopamine-beta-hydroxylase inhibitors
ZA853670B (en) Substituted lactams useful as angiotensin converting enzyme inhibitors
IE900618L (en) Angiotensin converting enzyme inhibitors
IL69474A0 (en) Angiotensin-converting enzyme inhibitors